EyePoint (EYPT) Share-based Compensation (2010 - 2026)
EyePoint (EYPT) posted Share-based Compensation of $58.3 million for Q1 2026, up 2464.89% sequentially from $2.3 million in Q4 2025, and up 6356.26% YoY from $903000.0 in Q1 2025.
EyePoint (EYPT) Share-based Compensation (2010 - 2026) Analysis & Trends
EyePoint has reported Share-based Compensation for 17 years, with the latest figure at $58.3 million in Q1 2026.
- Quarterly Share-based Compensation rose 6356.26% year-over-year to $58.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.3 million (up 260.52% YoY) and the FY2025 annual result came in at $21.3 million, down 42.03% from the prior year.
- Share-based Compensation grew to $58.3 million in Q1 2026 per EYPT's latest filing, from $2.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $58.3 million in Q1 2026 and troughed at -$8.5 million in Q4 2023.
- A 5-year average of $6.2 million and a median of $3.2 million in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation jumped 67120.0% in 2022, then slumped 351.92% in 2023.
- Over 5 years, Share-based Compensation stood at $3.4 million in 2022, then plunged by 351.92% to -$8.5 million in 2023, then soared by 193.3% to $7.9 million in 2024, then sank by 71.23% to $2.3 million in 2025, then soared by 2464.89% to $58.3 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $58.3 million, $2.3 million, and -$132000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 50.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.40 Mn |
| Jun 30, 2026 | 50.40 Mn |
| Mar 31, 2026 | 58.30 Mn |
| Mar 31, 2026 | 58.30 Mn |
| Dec 31, 2025 | 2.27 Mn |
| Dec 31, 2025 | 2.27 Mn |
| Sep 30, 2025 | -132,000.00 |
| Sep 30, 2025 | -132,000.00 |
| Jun 30, 2025 | 6.43 Mn |
| Jun 30, 2025 | 6.43 Mn |
| Mar 31, 2025 | 903,000.00 |
| Mar 31, 2025 | 903,000.00 |
| Dec 31, 2024 | 7.90 Mn |
| Dec 31, 2024 | 7.90 Mn |
| Sep 30, 2024 | 7.45 Mn |
| Sep 30, 2024 | 7.45 Mn |
| Jun 30, 2024 | -78,000.00 |
| Jun 30, 2024 | -78,000.00 |
| Mar 31, 2024 | 12.70 Mn |
| Mar 31, 2024 | 12.70 Mn |